Regeneron price target lowered to $812 from $940 at Truist

Truist lowered the firm’s price target on Regeneron (REGN) to $812 from $940 and keeps a Buy rating on the shares. The near-term investor focus remains on the Eylea tail and Eylea HD uptake, though Regeneron continues to deliver growth on its top and bottom line with Dupi and Libtayo programs, the analyst tells investors in a research note. Truist adds that it sees near-term value inflection points with additional launches and label expansions, along with a robust and maturing pipeline.